For research use only. Not for therapeutic Use.
Octreotide is a synthetic long-acting cyclic octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. Octreotide is a more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. Similar to somatostatin, this agent also suppresses the luteinizing hormone response to gonadotropin-releasing hormone, decreases splanchnic blood flow, and inhibits the release of serotonin, gastrin, vasoactive intestinal peptide (VIP), secretin, motilin, pancreatic polypeptide, and thyroid stimulating hormone.
| Catalog Number | I008400 |
| CAS Number | 79517-01-4 (acetate); 83150-76-9 (free base). |
| Synonyms | Longastatin; Sandostatin; Longastatina; Samilstin; Sandostatina; Sandostatine; SMS 201995;1-((4R,7S,10S,13R,16S,19R)-13-((1H-indol-3-yl)methyl)-19-((R)-2-amino-3-phenylpropanamido)-10-(4-aminobutyl)-16-benzyl-4-(((2R,3R)-1,3-dihydroxybutan-2-yl)carba |
| Molecular Formula | C55H76N10O15S2 |
| Purity | ≥95% |
| Target | Neuronal Signaling |
| Solubility | Soluble in DMSO, not in water |
| Storage | 0 - 4 °C for short term, or -20 °C for long term |
| Reference | </br>1:[The Use of Octreotide Acetate in the Management of Refractory Chylothorax Following Surgical Treatment for Lung Cancer]. Kawakami T, Ishida I, Sugawara T, Oura H.Kyobu Geka. 2016 Jun;69(6):429-32. Japanese. PMID: 27246125 </br>2:Treatment of Gastrin-Secreting Tumor With Sustained-Release Octreotide Acetate in a Dog. Kim S, Hosoya K, Takagi S, Okumura M.J Am Anim Hosp Assoc. 2015 Nov-Dec;51(6):407-12. doi: 10.5326/JAAHA-MS-6270. PMID: 26535461 </br>3:A rapid hydrolysis method and DABS-Cl derivatization for complete amino acid analysis of octreotide acetate by reversed phase HPLC. Akhlaghi Y, Ghaffari S, Attar H, Alamir Hoor A.Amino Acids. 2015 Nov;47(11):2255-63. doi: 10.1007/s00726-015-1999-9. Epub 2015 May 23. PMID: 26002809 </br>4:Stability of octreotide acetate decreases in a sodium bisulfate concentration-dependent manner: compatibility study with morphine and metoclopramide injections. Tanabe K, Wada J, Ohkubo J, Nitta A, Ikezaki T, Takeuchi M, Handa A, Tanaka M, Murakami N, Kashii T, Kitazawa H.Eur J Hosp Pharm Sci Pract. 2015 May;22(3):171-175. Epub 2015 Jan 16. PMID: 25984298 Free PMC Article</br>5:[Successful treatment of a case of chylothorax, manifesting as a complication following surgical treatment of coarctation of the aorta, by using octreotide acetate; report of a case]. Matsushita H, Hanayama N.Kyobu Geka. 2014 Feb;67(2):149-52. Japanese. PMID: 24743487 </br>6:Octreotide acetate-steroid combination therapy for malignant gastrointestinal obstruction. Murakami H, Matsumoto H, Nakamura M, Hirai T, Yamaguchi Y.Anticancer Res. 2013 Dec;33(12):5557-60. PMID: 24324097 </br>7:Octreotide acetate administration for malignant bowel obstruction induces severe bradycardia in patients with terminal stage cancer: two case reports. Kubota K, Hasumi Y, Numata A, Tukazaki T, Horie K, Hashimoto K, Yokota H.J Palliat Med. 2013 Jun;16(6):596-7. doi: 10.1089/jpm.2012.0564. Epub 2013 Apr 21. No abstract available. PMID: 23600413 </br>8:Hypercalcemia appeared in a patient with glucagonoma treated with octreotide acetate long-acting release. Rui M, Li L, Jiang-Feng M, Feng G, Hui-Juan Z, Wen-Hui L, Yu-Xiu L.Chin Med Sci J. 2012 Sep;27(3):182-4. PMID: 23062642 </br>9:[Postoperative refractory chylothorax which was improved by octreotide acetate]. Gabe A, Seki M, Taira N, Katsura M, Ishida T, Kang Y, Kubota T, Yamashiro T, Uehara T, Sunagawa T, Ohkubo K.Kyobu Geka. 2012 Mar;65(3):230-3. Japanese. PMID: 22374601 </br>10:Resolution of a posttraumatic pancreatic pseudocyst with octreotide acetate in a pediatric patient. Wensil AM, Balasubramanian SA, Bell TL.Pharmacotherapy. 2011 Sep;31(9):924. doi: 10.1592/phco.31.9.924. PMID: 21923595 |
; 83150-76-9 (free base)..gif)